RGEN
HoldPremium GrowerRepligen Corporation · Healthcare · United States · $9.9B · Avg Vol: $171M/d
Premium Grower: Strong business with the market behind it, but you are paying up for it.
ABOUT REPLIGEN CORPORATION
Read
Repligen Corporation is a leading provider of advanced bioprocessing technologies and consumables essential for the development and commercial manufacturing of biologics and gene therapies. The company's innovative product portfolio, including filtration systems, chromatography media, and protein reagents, establishes it as a critical supplier within the rapidly expanding biopharmaceutical industry. Repligen benefits from proprietary technologies and deep customer embeddedness in vital production workflows.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 801.5M | 632.4M | 634.4M | 738.3M | -2.7% | 785.1M | 826.9M | 974.4M | 14.9% |
| EPS | 3.35 | 0.75 | -0.46 | 0.87 | -36.2% | 0.73 | 1.05 | 1.35 | 24.5% |
| Shares | 55.6M | 55.8M | 56.1M | 56.3M | +1.4% | 56.4M | — | — | — |
| Debt | 423.0M | 711.8M | 686.2M | 689.9M | 17.7% | 690.9M | — | — | — |
| Equity | 1.9B | 2.0B | 2.0B | 2.1B | 3.3% | — | — | — | — |
| Op CF | 172.1M | 113.9M | 175.4M | 117.4M | -12.0% | 134.9M | — | — | — |
| Inv CF | -233.2M | -123.3M | -86.4M | -298.5M | — | — | — | — | — |
| Fin CF | -13.3M | 249.0M | -82.9M | -15.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of RGEN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| RGEN | Repligen Corporation(you) | $9.9B | 50 | Hold |
| AVTR | Avantor, Inc. | $9.9B | 70 | Buy |
| COO | The Cooper Companies, Inc. | $13.9B | 64 | Hold |
| MMED | MiniMed Group, Inc. | $5.7B | 40 | Hold |
| TFX | Teleflex Incorporated | $5.9B | 66 | Buy |
| ATR | AptarGroup, Inc. | $8.5B | 74 | Buy |
| BAX | Baxter International Inc. | $13.5B | 73 | Buy |
| ICUI | ICU Medical, Inc. | $4.4B | 63 | Hold |
| BLFS | BioLife Solutions, Inc. | $1.8B | 50 | Hold |
| LMAT | LeMaitre Vascular, Inc. | $1.8B | 53 | Hold |
Peer medians: ROE -31.0% · P/E 25.0x · Gross margin 58.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.